Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics.
Beta-lactam antibiotics (BLAs) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x.
Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Samira
S
Dahesh
Mary E
ME
Hensler
Nina M
NM
Van Sorge
Robert E
RE
Gertz
Stephanie
S
Schrag
Victor
V
Nizet
Bernard W
BW
Beall
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024881:Drug Resistance, Bacterial / Q000235:genetics; D008826:Microbial Sensitivity Tests; D008957:Models, Genetic; D008969:Molecular Sequence Data; D046915:Penicillin-Binding Proteins / Q000235:genetics*; D017354:Point Mutation; D017386:Sequence Homology, Amino Acid; D013292:Streptococcus agalactiae / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D046915:Penicillin-Binding Proteins; D047090:beta-Lactams; C072223:PBP 2x protein, Streptococcus